What is happening with Iovance Biotherapeutics Inc (IOVA) Stock?

Goldman raised the price target for the Iovance Biotherapeutics Inc (NASDAQ:IOVA) stock to “a Buy”. The rating was released on November 20, 2023, according to finviz. We previously noted in another research note published on September 18, 2023 by Barclays that reiterated the stock to an Overweight with a price target of $18 for IOVA stock. The research report from Wells Fargo has upgraded the stock from Equal Weight to Overweight, with a price target set at $17. The stock was resumed by Wells Fargo, who disclosed in a research note on March 27, 2023, to Equal Weight and set the price objective to $11. In their research brief published January 27, 2023, Piper Sandler analysts upgraded the Iovance Biotherapeutics Inc stock from Neutral to Overweight with a price target of $14.

The latest trade, Performances and Moving Averages give us the following Picture

The firm’s stock price fluctuated -5.53% within the last five trades and -10.81% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 211.18% in the last 6 months and 65.38% was added to its value over the previous 3 months. IOVA stock is trading at a margin of -6.38%, 15.55% and 82.57% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


As of the close of trading, IOVA deals in the Healthcare domain. The stock is trading -22.59 percent below its 52-week high and 342.06 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 64.3. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Iovance Biotherapeutics Inc’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at -38734.99 percent and the profit margin is -37345.42 percent, and the company has reported a gross margin of -3091.17 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $3.96 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 3330.60 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 6.22, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 21.24 percent of Iovance Biotherapeutics Inc shares are owned by insiders, and 67.26 percent are held by financial institutions. Rothbaum Wayne P., the Director at Iovance Biotherapeutics Inc (IOVA) has bought 5,000,000 shares of firm on Feb 20 ’24 at a price of $9.15 against the total amount of $45.75 million. In another inside trade, MCPEAK MERRILL A, Director of Iovance Biotherapeutics Inc (NASDAQ:IOVA) bought 250,000 shares of the firm on Feb 20 ’24 for a total worth of $2.29 million at a price of $9.15. An inside trade which took place on Feb 20 ’24, Director of Iovance Biotherapeutics Inc Dukes Iain D. bought 32,000 shares of firm against total price of $0.29 million at the cost of $9.15 per share.

Most Popular

Related Posts